There are certain cancer types, however, that are particularly appealing to this shift in the administration form, as it is the case of non-small-cell lung cancer (NSCLC) whose treatment is currently targeted at specific mutations, namely, epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1, and receptor tyrosine kinase (ROS1) (Geynisman and Wickersham, 2013; Majem and Pallarès, 2013). Here, ROS1 is linked to non-small cell lung carcinoma.